Revance Therapeutics、Crown Labs的要约收购延长至10月18日

Revance Therapeutics (NASDAQ:RVNC) said Crown Laboratories will extend the tender offer as Revance continues talks with Teoxane over a dispute. 

The tender offer was extended to Oct. 18 as it was set to expire today, according to an 8-K filing on Friday. Revance's ongoing talks with Teoxane and the buyer parties could result in further delays to the commencement or consummation of the tender. The tender offer was earlier delayed last month. 

Revance (RVNC) disclosed late last month that on Aug. 16 it received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the company’s exclusive distribution agreement with Teoxane.

Crown Labs agreed to acquire Revance Therapeutics (RVNC) for $6.66 a share in cash in August.